HC Wainwright Lifts Earnings Estimates for Orchestra BioMed

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Equities research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Orchestra BioMed in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.33) per share for the quarter, up from their prior estimate of ($0.42). The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.53) EPS.

Several other brokerages have also commented on OBIO. Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a research note on Thursday, March 12th. Barclays increased their target price on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.80.

Orchestra BioMed Price Performance

Shares of OBIO stock opened at $4.51 on Wednesday. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $5.42. The company has a current ratio of 6.45, a quick ratio of 6.43 and a debt-to-equity ratio of 0.27. The stock has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $3.89. The stock has a market capitalization of $263.93 million, a price-to-earnings ratio of -3.99 and a beta of 0.56.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.38) by $0.64. The company had revenue of $30.92 million for the quarter, compared to the consensus estimate of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%.

Hedge Funds Weigh In On Orchestra BioMed

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Orchestra BioMed by 28.0% during the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of Orchestra BioMed in the 3rd quarter worth approximately $3,386,000. Pathstone Holdings LLC bought a new position in shares of Orchestra BioMed during the 3rd quarter worth approximately $2,495,000. Geode Capital Management LLC raised its stake in shares of Orchestra BioMed by 22.4% during the 4th quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock worth $1,965,000 after acquiring an additional 86,564 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Orchestra BioMed by 46.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock valued at $1,095,000 after acquiring an additional 83,349 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.

Insider Activity at Orchestra BioMed

In related news, insider David P. Hochman acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the insider directly owned 1,086,467 shares of the company’s stock, valued at $4,660,943.43. This trade represents a 0.93% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 8.10% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.